Table 1 Clinicopathological characteristics of 90 HER2-negative metastatic breast cancer patients with detectable CTCs in the peripheral blood samples at baseline
Characteristic | Number of patients (%) |
|---|---|
Age (years) | |
< 40 | 9 (10.0) |
≥ 40 to < 60 | 64 (71.1) |
≥ 60 | 17 (18.9) |
Menstrual status | |
Premenopausal | 31 (34.4) |
Menopausal | 59 (65.6) |
ER status | |
Positive | 71 (78.9) |
Negative | 19 (21.1) |
PR status | |
Positive | 66 (73.3) |
Negative | 24 (26.7) |
HR status | |
Positive | 74 (82.2) |
Negative | 16 (17.8) |
Disease-free survival (months) | |
≤ 12 | 18 (20.0) |
> 12 to ≤ 24 | 9 (10.0) |
> 24 to ≤ 60 | 34 (37.8) |
> 60 | 29 (32.2) |
Number of metastases | |
Single | 4 (4.4) |
Multiple | 86 (95.6) |
Position of metastatic site | |
Non-visceral | 31 (34.4) |
Visceral | 59 (65.6) |
Previous endocrinotherapy (after confirmed tumor relapse) | |
None | 71 (78.9) |
First-line | 15 (16.7) |
Second-line or more | 4 (4.4) |